linjc16/ctgov huggingface dataset:
Association Between TMD and LBP Back Pain

Study Overview
=================
Brief Summary
-----------------
Investigate the relationships between temporomandibular disorder and low back pain

Detailed Description
-----------------
Some patients with chronic low back pain reveal temporomandibular disorder,and others do not. So the aims of my study were to find out the risk factors that contribute to the concurrence of temporomandibular disorder.

Official Title
-----------------
Association Between Temporomadibular Disorder and Low Back Pain

Conditions
-----------------
Conditions

Intervention / Treatment
-----------------
* Device: balance assessment with Biodex balance system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unilateral LBP for more than 1 year Exclusion Criteria: sensory or neurologic disorders; structural defect of the spine or lower extremities; a history of spine or TMD surgery; recent hip, knee, or ankle pain; any medication that could affect balance; a history of uncorrected visual impairment; and vestibular disorders.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: temporomandibular disorder group<br>subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system | Device: balance assessment with Biodex balance system<br>* All subjects of three groups will be assessed with the evaluation device( balance system).<br>|
| Active Comparator: chronic low back pain group<br>subjects only with LBP symptoms undergo balance assessment with Biodex balance system | Device: balance assessment with Biodex balance system<br>* All subjects of three groups will be assessed with the evaluation device( balance system).<br>|
| Other: Normal<br>subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system | Device: balance assessment with Biodex balance system<br>* All subjects of three groups will be assessed with the evaluation device( balance system).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| balance assesment | The subjects from three groups all receive the balance assessment with the Biodex balance system, and compare the difference. | only measure the balance performance before the treatment |
Electrical Stimulation and Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether electrical stimulation is effective in the expression of VEGF, VEGFR-2, HIF-1α and NO and healing in diabetic foot ulcer.

Detailed Description
-----------------
30 type 2 diabetic patients with ischemic foot ulceration were enrolled. Patients were randomly assigned to electrical stimulation (ES, n=15) or sham ES (placebo, n=15) groups. ES group received cathodal direct current for 1 h/day, 3 days/week, for 4 weeks (12 sessions). Wound fluid sample was collected for VEGF, VEGFR-2, HIF-1α and NO measurement in the first and last treatment sessions before and after intervention. Wound surface area (WSA) was measured at 1st, 6th, and 12th session.

Official Title
-----------------
The Effect of Electrical Stimulation on the Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer

Conditions
-----------------
Diabetic Foot

Intervention / Treatment
-----------------
* Procedure: Electrical Stimulation
* Procedure: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ischemic diabetic foot ulcer Wagner classification DFU 2 0.5<ABI<0.9 Mild to moderate diabetic neuropathy Exclusion Criteria: Fracture in a lower limb A severe infection A malignancy Kidney failure Skin diseases Osteomyelitis Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Electrical stimulation<br>In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions) | Procedure: Electrical Stimulation<br>* Direct current with sensory intensity for one hour<br>* Other names: Direct current ES;|
| Placebo Comparator: Placebo<br>In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero | Procedure: Placebo<br>* Direct current with zero intensity for one hour<br>* Other names: Placebo Direct current ES;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The wound fluid level of VEGF, VEGFR-2, HIF-1α and NO (pg/ml) |  | Change from Baseline in wound fluid level of VEGF, VEGFR-2, HIF-1α and NO at 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound surface area(cm2) |  | Change from Baseline in wound surface area at 2 and 4 weeks |
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Study Overview
=================
Brief Summary
-----------------
Although initially responsive to cytoreductive surgery and platinum- and/or taxane-based chemotherapy, a majority of patients with epithelial ovarian cancer, cancer of the fallopian tube or the peritoneum will eventually relapse. Recurrence within 6 months after completing platinum-containing chemotherapy indicates a platinum-refractory cancer disease. New therapeutic strategies are required in platinum-refractory disease. Inhibition of growth signals induced by the epidermal growth factor receptor pathway, or by the estrogen receptor pathway provides promising targets in epithelial ovarian cancer, cancer of the fallopian tube or the peritoneum. The trial is to evaluate the safety and tolerability of the combination of the epidermal growth facto tyrosine kinase inhibitor ZD1839 and the clinically established antiestrogen tamoxifen.

Official Title
-----------------
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Conditions
-----------------
Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer

Intervention / Treatment
-----------------
* Drug: ZD1839
* Drug: tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically confirmed epithelial ovarian cancer, cancer of the fallopian tube or peritoneum refractory to platinum- and taxane-based chemotherapy measurable or non-measurable disease written informed consent aged 18 years or older Karnofsky performance status > 60% Exclusion Criteria: complete bowel obstruction symptomatic brain metastases known hypersensitivity to evaluated drugs inadequate kidney function inadequate hepatic function evidence of clinically active interstitial lung disease history of congestive heart failure > NYHA 2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ZD1839|nan|
|Drug: tamoxifen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| objective response rate |  |  | 
| time to progression |  |  | 
| overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer, cancer alternative therapies, ovarian cancer, tyrosine kinase inhibitor
Contrast Sensitivity in Glaucoma

Study Overview
=================
Brief Summary
-----------------
The primary aim of the Erlangen´s Glaucoma Contrast Sensitivity-Study (EGCS-Study) is the evaluation of the diagnostic and prognostic validity of a diagnostic procedure, measuring contrast sensitivity. No therapeutic studies are performed.

Official Title
-----------------
Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)

Conditions
-----------------
Primary Open Angle Glaucoma, Secondary Open Angle Glaucoma Due to PEX

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX Healthy volunteers (for reliability analysis) Inclusion Criteria: Age > 18 Best corrected visual acuity 0.8 or better European Exclusion Criteria: eye diseases: Infantile glaucoma, angle glaucoma, secondary open angle glaucoma, wich are not due to PEX, diseases involving retina, condition after ophthalmological operations or trauma, cataract, diseases concerning the refractive system, age-related macular degeneration, diabetic retinopathy, optic neuropathy (MS, neuritis), amblyopia Any neurological diseases Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus) Systemic drugs with potentially ocular involvement ocular drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction

Study Overview
=================
Brief Summary
-----------------
Evaluation of efficacy and safety of H-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.

Conditions
-----------------
Marijuana Abuse

Intervention / Treatment
-----------------
* Device: H-Coil deep TMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and Female, aged 21-70 years, who meet DSM-IV TR diagnostic criteria for cannabis abuse and are motivated to quit cannabis use as assessed in the screening visit and gave their written informed consent to participate in the study. Exclusion Criteria: History of a primary major psychiatric other then cannabis abuse, or cognitive disorder according to DSM-IV TR criteria. Hamilton depression scale rated 25 and above (moderate to severe depression) Current alcohol or other substance abuse or dependence Alcohol or other substance abuse or dependence during the last 12 months before recruitment. History of or evidence of significant brain malformation,neoplasm, head injury, cerebral vascular events,neurodegenerative disorder or brain surgery. Severe somatic co-morbidity History of seizures Cardiac pace maker or other electronic implants Pregnancy and lactation

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: H-Coil deep TMS|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cannabis, Addiction, Craving, TMS
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Study Overview
=================
Brief Summary
-----------------
This 3 arm study will determine the dose of R1507 which will achieve a mean drug exposure in children and adolescents with advanced solid tumors equivalent to the exposure achieved in adults at the recommended dose of 9mg/kg/week. It will also determine the maximum tolerated dose (if appropriate) and the pharmacokinetic profile of R1507. Groups of patients will be sequentially enrolled in one of up to 3 dose levels (3,9mg/kg or a PK-derived dose, not to exceed 16 mg/kg) of R1507 administered weekly by intravenous infusion.An expanded cohort of patients will be enrolled at the optimal dose/MTD. The anticipated time on study treatment is until disease progression or dose limiting toxicity, and the target sample size is <100 individuals.

Official Title
-----------------
Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.

Conditions
-----------------
Neoplasms

Intervention / Treatment
-----------------
* Drug: RG1507
* Drug: RG1507
* Drug: RG1507


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients aged 2-17 years of age; histologically confirmed solid tumors; cancer which has relapsed after, or failed to respond to, curative therapy, or no other potentially curative treatment options available. Exclusion Criteria: treatment with corticosteroids within past 2 weeks; current or past use of anti-IGF-1R antibodies; current treatment with immunosuppressive agents; patients with diabetes mellitus; known HIV or hepatitis B or C; hypersensitivity to any of the components of R1507 or to monoclonal antibodies.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: RG1507<br>* 3mg/kg iv weekly<br>|
| Experimental: 2<br> | Drug: RG1507<br>* 9mg/kg iv weekly<br>|
| Experimental: 3<br> | Drug: RG1507<br>* Pharmacokinetic-derived dose, <=16mg/kg iv weekly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum drug exposure level equivalent to exposure in adults at adult recommended dose. |  | Throughout study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MTD (AEs, laboratory parameters) |  | Throughout study |
Observational Trial of a Therapeutic Platelet Transfusion Regimen

Study Overview
=================
Brief Summary
-----------------
Application of a therapeutic platelet transfusion Regimen in patients with acute myeloid leukemia in complete Remission (consolidation therapy)

Detailed Description
-----------------
For the participants a therapeutic regimen for platelet transfusions will be applied: for clinically stable patients platelet Transfusion will be given in case of bleeding WHO II° or higher, for clinically instable patients platelet transfusion will be given at the decretion of the attending physician. Patients with sepsis, septic shock or infections with Infiltration of organs (e.g. invasive aspergillosis), plasmatic coagulation disorders or sudden or increasing headache with or without neurologic symptoms should receive prophylactic platelet Transfusion, if their platelet Count is less then 10/nl. Otherwise no prophylactic platelet Transfusion will be given irrespective of the actual platelet Count. As Primary study endpoint The incidence of bleeding episodes WHO grade III an IV will be documented. The bleeding incidence will then be compared to a historic cohort.

Official Title
-----------------
A Prospective Multicenter Observational Trial of a Therapeutic Platelet Transfusion Regimen for Patients With Acute Myeloid Leukemia in Consolidation Chemotherapy

Conditions
-----------------
Acute Myeloid Leukemia, Thrombocytopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute myeloid leukemia in complete remission Exclusion Criteria: plasmatic coagulopathy history of severe bleeding complications in chemotherapy induced thrombocytopenia no increment in platelets after platelet transfusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding Grade III and IV (WHO) |  | Patients will be followed for the phase of thrombocytopenia after chemotherapy, an expected average of about 14 days. |
Hospital Ederly Life Program for Surgical Patients

Study Overview
=================
Brief Summary
-----------------
Frailty is the clinically recognizable medical condition, also called syndrome or phenotype, that is, the result of processes leading to an increased vulnerability for serious deteriorations in health and the diminished ability to cope with physical stressors. Recently, frailty has emerged as a significant risk factor for adverse postoperative outcomes. It is related to declines in energy, strength, and function as well as to an increased inflammatory state, including elevated levels of interleukin 6 (IL-6), C-reactive protein (CRP), and anelevated white blood cell count . Frailty, as defined Frailty, as defined in the landmark paper by Fried, included at least three of five of the following criteria: unintentional loss of weight, low physical activity, low energy, low grip strength, and a slowed walking speed. Since then, various frailty scoring lists have been designed to optimize the predictive value. One of these is the Edmonton Frail Scale (EFS), an instrument that can be assessed quickly, using only a simple questionnaire which usually does not require more than five minutes to be completed and which covers most domains of functioning, making it easy and fast to get a reliable impression of the degree of frailty.The aim of this study was to determine which factors,with emphasis on frailty, significantly influence postoperative outcome after elective noncardiac surgery as measured by the Comprehensive Complication Index (CCI).

Official Title
-----------------
Effects of Frailty on Outcomes After Elective Noncardiac Surgery -a Prospective Cohort Study

Conditions
-----------------
To Investigate the Mortality of the Frailty Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective noncardiac surgery Exclusion Criteria: patients who don't cooperate

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| frailty<br> | |
| nonfrailty<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| one-year mortality | To investigate the one-year mortality of the frailty patients | 2019.02-2020.02 |
Epidemiology of H. Pylori Transmission

Study Overview
=================
Brief Summary
-----------------
This observational epidemiologic study with nested cross-sectional and longitudinal aims will evaluate host immune response to mixed chronic infections (Helicobacter pylori, latent tuberculosis, intestinal helminthiasis) in recent US immigrants.

Detailed Description
-----------------
1750 clinically-well, adult (age 18-55 years), recent immigrants (<2 years U.S. residence), referred through cooperating public health clinics in the Santa Clara Valley area, CA will be screened for H. pylori, helminth, and latent tuberculosis infections [Screening population]. Of these 1750, 426 will be selected for more intensive study (Cohort population), 105 of whom will receive baseline endoscopy. Of those selected for the cohort, 300 are expected to complete a 9-month follow-up assessment, 75 of whom are expected to undergo a second follow-up endoscopy.

Official Title
-----------------
Epidemiology of H. Pylori Transmission and Immunoepidemiology of Concomitant Infections

Conditions
-----------------
Communicable Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 18-55 years of age Either sex If female not pregnant or breastfeeding Lived in the United States less than 2 years Healthy Scheduled for Tuberculosis Skin Test (TST) Exclusion Criteria: Under 18 and older than 55 years of age, Pregnant or breastfeeding Have lived in Unites States more that 2 years Chronic illness Not planning to get a TST

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cytokine responses from baseline at 9 months in TB and H. pylori antigen-induced PBMC before and after provider managed treatment of latent TB or helminth infection |  | Baseline and 9 months after treatment for either latent TB or helminth infections; analyzed after all subjects recruited (3 years of recruitment plus 9 months follow-up). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of cytokine response to TB antigens and helminths with humoral responses to infections with H. pylori. |  | Assays performed when collected over three years from recruited subjects; analyzed at the end of three years. | 
| Population prevalence of individual and joint infections with H pylori, latent tuberculosis, heminthiasis in recent immigrant to northern California | We compare prevalence of these infections in recent immigrants by geographic area | Assays performed when collected over three years from recruited subjects; analyzed at the end of three years. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic coinfection